

Anthony Lucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9115058/publications.pdf>

Version: 2024-02-01

219
papers

15,058
citations

18482

62
h-index

20358

116
g-index

226
all docs

226
docs citations

226
times ranked

18714
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Therapeutics of Oxidative Stress and Stemness in Breast Cancer. , 2022, , 1765-1776. | | 0 |
| 2 | Trends in Sentinel Lymph Node Biopsies in Patients With Inflammatory Breast Cancer in the US. JAMA Network Open, 2022, 5, e2148021. | 5.9 | 1 |
| 3 | Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022, 6, e2000368. | 3.0 | 9 |
| 4 | Utilization and evolving prescribing practice of opioid and nonopioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. Journal of Surgical Oncology, 2022, 125, 719-729. | 1.7 | 1 |
| 5 | Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. Journal of Investigative Dermatology, 2022, 142, 2046-2049.e3. | 0.7 | 8 |
| 6 | Immediate Breast Reconstruction in Inflammatory Breast Cancer: Are We There Yet?. Annals of Surgical Oncology, 2022, , . | 1.5 | 3 |
| 7 | Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers, 2022, 14, 2631. | 3.7 | 1 |
| 8 | Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803. | 27.8 | 54 |
| 9 | Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. International Journal of Molecular Sciences, 2022, 23, 7843. | 4.1 | 15 |
| 10 | Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 4615-4622. | 1.5 | 14 |
| 11 | ASO Author Reflections: The Multidisciplinary Approach to de Novo Metastatic Inflammatory Breast Cancer: A Combined Systemic and Locoregional Strategy. Annals of Surgical Oncology, 2021, 28, 4275-4276. | 1.5 | 0 |
| 12 | The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 4265-4274. | 1.5 | 11 |
| 13 | Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. Oncotarget, 2021, 12, 626-637. | 1.8 | 9 |
| 14 | Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489. | 1.5 | 7 |
| 15 | ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 458-459. | 1.5 | 2 |
| 16 | ASO Author Reflections: Metastasis of Inflammatory Breast Cancer to the Contralateral Axilla: A Finding Meriting Further Study. Annals of Surgical Oncology, 2021, 28, 8622-8623. | 1.5 | 0 |
| 17 | Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 8610-8621. | 1.5 | 7 |
| 18 | Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. Journal of Surgical Oncology, 2021, 124, 989-994. | 1.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 5477-5485. | 1.5 | 3 |
| 20 | Inflammatory Breast Cancer at the Extremes of Age. <i>Annals of Surgical Oncology</i> , 2021, 28, 5626-5634. | 1.5 | 5 |
| 21 | Current Surgical Management of Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5461-5467. | 1.5 | 17 |
| 22 | Cell-free circulating tumor DNA profiling in cancer management. <i>Trends in Molecular Medicine</i> , 2021, 27, 1014-1015. | 6.7 | 17 |
| 23 | ASO Visual Abstract: Inflammatory Breast Cancer at the Extremes of Age. <i>Annals of Surgical Oncology</i> , 2021, 29, 389. | 1.5 | 2 |
| 24 | ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2021, , 1. | 1.5 | 0 |
| 25 | Contemporary surgical management of inflammatory breast cancer: a narrative review. <i>Chinese Clinical Oncology</i> , 2021, 10, 57-57. | 1.2 | 6 |
| 26 | Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020, 9, 1025-1032. | 2.8 | 19 |
| 27 | Mammalian Expression and <i>In Situ</i> Biotinylation of Extracellular Protein Targets for Directed Evolution. <i>ACS Omega</i> , 2020, 5, 25440-25455. | 3.5 | 2 |
| 28 | ASO Author Reflection: Axillary Dissection for Negative Lymph Nodes in Inflammatory Breast Cancer—Need for Clinical Trials to Reassess Standard of Care. <i>Annals of Surgical Oncology</i> , 2020, 27, 676-677. | 1.5 | 1 |
| 29 | Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4603-4612. | 1.5 | 12 |
| 30 | Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. <i>Cancers</i> , 2020, 12, 3105. | 3.7 | 1 |
| 31 | Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 683-687. | 2.5 | 2 |
| 32 | Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. <i>BMC Cancer</i> , 2020, 20, 430. | 2.6 | 4 |
| 33 | B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555. | 27.8 | 1,421 |
| 34 | Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441. | 1.6 | 23 |
| 35 | Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020, 215, 127-145. | 1.8 | 18 |
| 36 | Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 1886-1895. | 7.0 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3071-3079. | 1.5 | 19 |
| 38 | Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. <i>Practical Radiation Oncology</i> , 2019, 9, 402-409. | 2.1 | 8 |
| 39 | The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database. <i>Journal of Translational Medicine</i> , 2019, 17, 318. | 4.4 | 19 |
| 40 | The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. <i>Journal of Cancer</i> , 2019, 10, 2635-2642. | 2.5 | 3 |
| 41 | Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 856. | 3.7 | 31 |
| 42 | Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. <i>Journal of Surgical Research</i> , 2019, 243, 90-99. | 1.6 | 9 |
| 43 | Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 52-66. | 1.0 | 1 |
| 44 | Nipple sparing mastectomy for melanoma metastatic to the breast. <i>Breast Journal</i> , 2019, 25, 741-741. | 1.0 | 0 |
| 45 | OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 815-820. | 1.5 | 10 |
| 46 | Ductal Carcinoma In Situ and Margins $\leq 2\text{ mm}$. <i>Annals of Surgery</i> , 2019, 269, 150-157. | 4.2 | 29 |
| 47 | Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. <i>Oncotarget</i> , 2019, 10, 3681-3693. | 1.8 | 8 |
| 48 | Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 560-567. | 6.3 | 206 |
| 49 | Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193. | 10.7 | 233 |
| 50 | Molecular Prognostic Factors for Breast Carcinoma. , 2018, , 258-263.e2. | | 0 |
| 51 | Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e73-e77. | 2.4 | 28 |
| 52 | A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018, 267, 946-951. | 4.2 | 147 |
| 53 | Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. <i>Annals of Surgical Oncology</i> , 2018, 25, 512-519. | 1.5 | 23 |
| 54 | Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654. | 30.7 | 592 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching "liquid biopsy" and quantitative tumor modeling. BMC Cancer, 2018, 18, 903. | 2.6 | 14 |
| 56 | Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE, 2018, 13, e0204372. | 2.5 | 16 |
| 57 | Can Circulating Tumor Cell Monitoring Identify Optimal Candidates for Watch and Wait after Neoadjuvant Therapy for Rectal Cancer?. Journal of the American College of Surgeons, 2018, 227, S61. | 0.5 | 0 |
| 58 | Inflammatory Breast Cancer. Surgical Clinics of North America, 2018, 98, 787-800. | 1.5 | 63 |
| 59 | Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428. | 7.0 | 89 |
| 60 | International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer, 2018, 9, 1437-1447. | 2.5 | 84 |
| 61 | American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Annals of Surgical Oncology, 2018, 25, 2965-2974. | 1.5 | 16 |
| 62 | Circulating Tumor Cells in Stage IV Melanoma Patients. Journal of the American College of Surgeons, 2018, 227, 116-124. | 0.5 | 17 |
| 63 | Reply to "A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18". Breast, 2018, 39, 148-149. | 2.2 | 2 |
| 64 | Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology, 2018, 4, 1207. | 7.1 | 56 |
| 65 | Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.. Journal of Clinical Oncology, 2018, 36, 1065-1065. | 1.6 | 6 |
| 66 | A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence. Oncotarget, 2018, 9, 11071-11082. | 1.8 | 10 |
| 67 | Opioid prescriptions after breast cancer surgery: Perception and reality.. Journal of Clinical Oncology, 2018, 36, e18799-e18799. | 1.6 | 0 |
| 68 | Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272. | 2.5 | 27 |
| 69 | Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surgery, 2017, 152, 665. | 4.3 | 149 |
| 70 | Inflammatory breast cancer: a proposed conceptual shift in the UICC/AJCC TNM staging system. Lancet Oncology, The, 2017, 18, e228-e232. | 10.7 | 74 |
| 71 | Best practices for multidisciplinary integration of a DCIS genomic assay into clinical practice. Journal of Surgical Oncology, 2017, 116, 1016-1020. | 1.7 | 3 |
| 72 | Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Annals of Surgical Oncology, 2017, 24, 2981-2988. | 1.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery" the argument against breast conservation and sentinel lymph node biopsy in IBC. Breast Cancer Research and Treatment, 2017, 165, 779-781. | 2.5 | 4 |
| 74 | Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. American Journal of Surgery, 2017, 214, 666-671. | 1.8 | 8 |
| 75 | Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614. | 2.5 | 15 |
| 76 | Circulating Tumor Cells in Breast Cancer Patients. Critical Reviews in Oncogenesis, 2016, 21, 125-139. | 0.4 | 22 |
| 77 | Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Annals of Surgical Oncology, 2016, 23, 3190-3198. | 1.5 | 119 |
| 78 | Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control, 2016, 27, 359-366. | 1.8 | 38 |
| 79 | Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. Journal of Clinical Oncology, 2016, 34, 1741-1747. | 1.6 | 64 |
| 80 | Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. Journal of the American College of Surgeons, 2016, 223, 20-29. | 0.5 | 35 |
| 81 | Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research, 2016, 22, 2583-2593. | 7.0 | 289 |
| 82 | Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS ONE, 2016, 11, e0159072. | 2.5 | 94 |
| 83 | The relationship between blood IL-2p40 level and melanoma progression. International Journal of Cancer, 2015, 136, 1874-1880. | 5.1 | 5 |
| 84 | Detection of circulating melanoma cells in the blood of melanoma patients. Melanoma Research, 2015, 25, 335-341. | 1.2 | 19 |
| 85 | Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. European Journal of Cancer Care, 2015, 24, 724-733. | 1.5 | 31 |
| 86 | Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 242-247. | 1.3 | 26 |
| 87 | C-Reactive Protein As a Marker of Melanoma Progression. Journal of Clinical Oncology, 2015, 33, 1389-1396. | 1.6 | 71 |
| 88 | Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment, 2015, 152, 407-416. | 2.5 | 68 |
| 89 | Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. Journal of Investigative Dermatology, 2015, 135, 2266-2272. | 0.7 | 7 |
| 90 | Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage III Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2015, 22, 552-558. | 1.5 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv250. | 6.3 | 25 |
| 92 | Assessment of Practice Patterns Following Publication of the SSO's ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3250-3256. | 1.5 | 29 |
| 93 | Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents. <i>PLoS ONE</i> , 2014, 9, e109487. | 2.5 | 17 |
| 94 | Aldehyde Dehydrogenase1 Immunohistochemical Staining in Primary Breast Cancer Cells Independently Predicted Overall Survival But Did Not Correlate with the Presence of Circulating or Disseminated Tumors Cells. <i>Journal of Cancer</i> , 2014, 5, 360-367. | 2.5 | 11 |
| 95 | Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. <i>Annals of Oncology</i> , 2014, 25, 358-365. | 1.2 | 82 |
| 96 | Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 6.3 | 73 |
| 97 | Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. <i>Cancer Cell</i> , 2014, 26, 707-721. | 16.8 | 1,293 |
| 98 | Circulating tumor cells in non-metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 325-333. | 2.5 | 32 |
| 99 | Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. <i>Molecular and Clinical Oncology</i> , 2014, 2, 845-850. | 1.0 | 27 |
| 100 | Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma-In Situ Treated with Mastectomy: Is Further Therapy Warranted?. <i>Annals of Surgical Oncology</i> , 2013, 20, 4103-4112. | 1.5 | 48 |
| 101 | Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. <i>Annals of Oncology</i> , 2013, 24, 2515-2521. | 1.2 | 36 |
| 102 | Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. <i>SpringerPlus</i> , 2013, 2, 409. | 1.2 | 21 |
| 103 | Detection and prognostic significance of circulating tumor cells in nonmetastatic breast cancer patients. <i>Breast Cancer Management</i> , 2013, 2, 295-309. | 0.2 | 0 |
| 104 | Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. <i>Clinical Cancer Research</i> , 2013, 19, 4685-4696. | 7.0 | 130 |
| 105 | Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. <i>Melanoma Research</i> , 2013, 23, 290-297. | 1.2 | 47 |
| 106 | Discordance in <i>HER2</i> gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. <i>Cancer Medicine</i> , 2013, 2, 226-233. | 2.8 | 44 |
| 107 | Variability in melanoma post-treatment surveillance practices by country and physician specialty. <i>Melanoma Research</i> , 2012, 22, 376-385. | 1.2 | 48 |
| 108 | Evaluation of a Breast Cancer Nomogram for Predicting Risk of Ipsilateral Breast Tumor Recurrences in Patients With Ductal Carcinoma in Situ After Local Excision. <i>Journal of Clinical Oncology</i> , 2012, 30, 600-607. | 1.6 | 107 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Reduced Incidence of Breast Cancer-Related Lymphedema following Mastectomy and Breast Reconstruction versus Mastectomy Alone. <i>Plastic and Reconstructive Surgery</i> , 2012, 130, 1169-1178. | 1.4 | 61 |
| 110 | Reply to K.J. Van Zee et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 3144-3145. | 1.6 | 4 |
| 111 | Inflammatory Breast Cancer: What We Know and What We Need to Learn. <i>Oncologist</i> , 2012, 17, 891-899. | 3.7 | 127 |
| 112 | Circulating tumour cells in non-metastatic breast cancer: a prospective study. <i>Lancet Oncology</i> , The, 2012, 13, 688-695. | 10.7 | 474 |
| 113 | Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1381-1386. | 0.8 | 42 |
| 114 | Invasive lobular carcinoma predicts micrometastasis in breast cancer. <i>Journal of Surgical Research</i> , 2012, 177, 93-96. | 1.6 | 11 |
| 115 | Circulating and Disseminated Tumor Cells in Breast Cancer. <i>Breast Diseases</i> , 2012, 23, 314-317. | 0.0 | 0 |
| 116 | Changing Behavior in Clinical Practice in Response to the ACOSOG Z0011 Trial: A Survey of the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2012, 19, 3152-3158. | 1.5 | 85 |
| 117 | American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. <i>Annals of Surgical Oncology</i> , 2012, 19, 3144-3151. | 1.5 | 157 |
| 118 | Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. <i>Annals of Surgical Oncology</i> , 2012, 19, 3777-3784. | 1.5 | 67 |
| 119 | Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770. | 7.0 | 345 |
| 120 | Circulating tumour cells in early breast cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e371. | 10.7 | 0 |
| 121 | Selection of Metastatic Breast Cancer Cells Based on Adaptability of Their Metabolic State. <i>PLoS ONE</i> , 2012, 7, e36510. | 2.5 | 20 |
| 122 | Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1131-1141. | 2.5 | 7 |
| 123 | Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. <i>Cancer</i> , 2012, 118, 342-348. | 4.1 | 24 |
| 124 | Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. <i>International Journal of Cancer</i> , 2012, 130, 808-816. | 5.1 | 148 |
| 125 | Surgical Therapy for Inflammatory Breast Cancer. , 2012, , 67-73. | | 0 |
| 126 | International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. <i>Annals of Oncology</i> , 2011, 22, 515-523. | 1.2 | 407 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Micrometastatic Node-Positive Breast Cancer: Long-Term Outcomes and Identification of High-Risk Subsets in a Large Population-Based Series. <i>Breast Diseases</i> , 2011, 22, 51-53. | 0.0 | 0 |
| 128 | Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotype. <i>European Journal of Cancer</i> , 2011, 47, 1527-1536. | 2.8 | 89 |
| 129 | Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell Line. <i>Journal of Surgical Research</i> , 2011, 168, e39-e49. | 1.6 | 51 |
| 130 | Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning. <i>Annals of Surgery</i> , 2011, 253, 572-579. | 4.2 | 60 |
| 131 | Management of Local-Regional Recurrence following Immediate Breast Reconstruction in Patients with Early Breast Cancer Treated without Postmastectomy Radiotherapy. <i>Plastic and Reconstructive Surgery</i> , 2011, 127, 1763-1772. | 1.4 | 12 |
| 132 | Anti-cytokeratin CAM5.2 (BD Sciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage III Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2011, 18, 263-264. | 1.5 | 0 |
| 133 | Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. <i>Annals of Surgical Oncology</i> , 2011, 18, 2407-2412. | 1.5 | 113 |
| 134 | Ductal Carcinoma-In-Situ of the Breast with Subsequent Distant Metastasis and Death. <i>Annals of Surgical Oncology</i> , 2011, 18, 2873-2878. | 1.5 | 44 |
| 135 | Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 785-795. | 2.5 | 68 |
| 136 | Oncoplastics: Techniques for reconstruction of partial breast defects based on tumor location. <i>Journal of Surgical Oncology</i> , 2011, 103, 341-347. | 1.7 | 23 |
| 137 | Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. <i>Cancer</i> , 2011, 117, 39-47. | 4.1 | 59 |
| 138 | Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. <i>Cancer</i> , 2011, 117, 916-924. | 4.1 | 87 |
| 139 | Reply to detection of minimal residual disease in blood and bone marrow in early stage breast cancer. <i>Cancer</i> , 2011, 117, 2579-2579. | 4.1 | 0 |
| 140 | Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. <i>Cancer</i> , 2011, 117, 5476-5484. | 4.1 | 61 |
| 141 | Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 4882-4891. | 7.0 | 48 |
| 142 | Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. <i>Oncologist</i> , 2011, 16, 1675-1683. | 3.7 | 86 |
| 143 | Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. <i>Cancer Biology and Therapy</i> , 2011, 11, 812-815. | 3.4 | 19 |
| 144 | Prospective Assessment of Postoperative Complications and Associated Costs Following Inguinal Lymph Node Dissection (ILND) in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2010, 17, 2764-2772. | 1.5 | 139 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-------|-----------|
| 145 | Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. <i>Annals of Surgical Oncology</i> , 2010, 17, 2899-2908. | 1.5 | 74 |
| 146 | Disseminated Tumor Cells in Biologic Subtypes of Stage III Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2010, 17, 3252-3258. | 1.5 | 14 |
| 147 | Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2010, 17, 280-285. | 1.5 | 29 |
| 148 | Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 233-240. | 3.3 | 46 |
| 149 | Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 351-375. | 329.8 | 298 |
| 150 | Conditional survival estimates improve over time for patients with advanced melanoma. <i>Cancer</i> , 2010, 116, 2234-2241. | 4.1 | 74 |
| 151 | Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. <i>Cancer</i> , 2010, 116, 3330-3337. | 4.1 | 108 |
| 152 | Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. <i>Cancer</i> , 2010, 116, 2884-2889. | 4.1 | 194 |
| 153 | Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. <i>Cancer</i> , 2010, 116, 2806-2814. | 4.1 | 42 |
| 154 | The suture scaffold technique for improved cosmesis in partial mastectomy defects. <i>Journal of Surgical Oncology</i> , 2010, 102, 184-186. | 1.7 | 3 |
| 155 | Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 889-895. | 0.8 | 39 |
| 156 | Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. <i>Breast Journal</i> , 2010, 16, 529-532. | 1.0 | 24 |
| 157 | Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. <i>Molecular Cancer</i> , 2010, 9, 180. | 19.2 | 66 |
| 158 | Overexpression of COX-2 in Celecoxib-Resistant Breast Cancer Cell Lines. <i>Journal of Surgical Research</i> , 2010, 163, 235-243. | 1.6 | 15 |
| 159 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6639-6648. | 7.0 | 113 |
| 160 | A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. <i>Cancer</i> , 2009, 115, 1555-1562. | 4.1 | 91 |
| 161 | Lymph node ratio predicts disease-specific survival in melanoma patients. <i>Cancer</i> , 2009, 115, 2505-2513. | 4.1 | 60 |
| 162 | Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 61-68. | 2.5 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 501-507. | 2.5 | 73 |
| 164 | Improved Postoperative Pain Control using Thoracic Paravertebral Block for Breast Operations. <i>Breast Journal</i> , 2009, 15, 483-488. | 1.0 | 42 |
| 165 | Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. <i>Annals of Surgical Oncology</i> , 2009, 16, 1606-1611. | 1.5 | 50 |
| 166 | A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer. <i>Journal of Surgical Research</i> , 2009, 155, 231-236. | 1.6 | 159 |
| 167 | Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. <i>American Journal of Surgery</i> , 2009, 198, 720-725. | 1.8 | 66 |
| 168 | Is axillary dissection needed when the sentinel node is positive? No: It is time to rethink axillary lymph node dissection when the sentinel node is positive. <i>Journal of Surgical Oncology</i> , 2008, 97, 201-202. | 1.7 | 2 |
| 169 | How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. <i>Cancer</i> , 2008, 113, 30-37. | 4.1 | 78 |
| 170 | Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: A randomized controlled trial (NCT00506311). <i>World Journal of Surgical Oncology</i> , 2008, 6, 63. | 1.9 | 55 |
| 171 | Cyclooxygenase-2 Induces Genomic Instability, BCL2 Expression, Doxorubicin Resistance, and Altered Cancer-Initiating Cell Phenotype in MCF7 Breast Cancer Cells. <i>Journal of Surgical Research</i> , 2008, 147, 240-246. | 1.6 | 43 |
| 172 | Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. <i>American Journal of Surgery</i> , 2008, 196, 81-87. | 1.8 | 67 |
| 173 | Melanoma adrenal metastasis: natural history and surgical management. <i>American Journal of Surgery</i> , 2008, 195, 363-369. | 1.8 | 69 |
| 174 | 4â€“24 Nipple-Sparing Mastectomy for Breast Cancer and Risk Reduction: Oncologic or Technical Problem?. <i>Breast Diseases</i> , 2008, 18, 370-371. | 0.0 | 0 |
| 175 | Orthopedic surgery implications of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 949-956. | 2.4 | 4 |
| 176 | Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1463-1472. | 2.4 | 20 |
| 177 | Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial 20011. <i>Journal of Clinical Oncology</i> , 2007, 25, 3657-3663. | 1.6 | 741 |
| 178 | Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2007, 356, 1888-1889. | 27.0 | 6 |
| 179 | Cyclooxygenase-2 Expression Induces Genomic Instability in MCF10A Breast Epithelial Cells. <i>Journal of Surgical Research</i> , 2007, 140, 220-226. | 1.6 | 20 |
| 180 | Prospective Studies Confirm What We Have Thought All Alongâ€“Sentinel Lymph Node Dissection Really Is a Less Morbid Means of Axillary Staging. <i>Breast Diseases</i> , 2007, 18, 18. | 0.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | COX-2 involvement in breast cancer metastasis to bone. <i>Oncogene</i> , 2007, 26, 3789-3796. | 5.9 | 120 |
| 182 | Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin). <i>Breast Journal</i> , 2007, 13, 72-75. | 1.0 | 21 |
| 183 | Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. <i>American Journal of Surgery</i> , 2006, 192, 541-544. | 1.8 | 17 |
| 184 | COX-2 Induces IL-11 Production in Human Breast Cancer Cells. <i>Journal of Surgical Research</i> , 2006, 131, 267-275. | 1.6 | 72 |
| 185 | Involvement of IL-8 in COX-2-Mediated Bone Metastases from Breast Cancer. <i>Journal of Surgical Research</i> , 2006, 134, 44-51. | 1.6 | 66 |
| 186 | Surgical Treatment of Pregnancy Associated Breast Cancer. <i>Breast Disease</i> , 2006, 23, 87-93. | 0.8 | 12 |
| 187 | Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer. <i>Annals of Surgery</i> , 2006, 244, 464-470. | 4.2 | 135 |
| 188 | Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy. <i>Annals of Surgical Oncology</i> , 2006, 13, 310-320. | 1.5 | 120 |
| 189 | Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial. <i>Annals of Surgical Oncology</i> , 2006, 13, 491-500. | 1.5 | 506 |
| 190 | Intramammary Lymph Node Presenting as the Primary Breast Mass in Infiltrating Lobular Carcinoma. <i>Journal of Surgical Education</i> , 2006, 63, 107-109. | 0.7 | 3 |
| 191 | Lymphoscintigraphy Does Not Enhance Sentinel Node Identification or Alter Management of Patients With Early Breast Cancer. <i>Journal of Surgical Education</i> , 2006, 63, 207-212. | 0.7 | 13 |
| 192 | Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients. <i>Cancer</i> , 2006, 106, 188-195. | 4.1 | 35 |
| 193 | The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. <i>Cancer</i> , 2006, 107, 1248-1254. | 4.1 | 44 |
| 194 | RE: Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer, by van Rijk MC, Tanis PJ, Nieweg OE, et al.. <i>Journal of Surgical Oncology</i> , 2006, 94, 266-268. | 1.7 | 2 |
| 195 | Atypical Dermatofibrosarcoma Protuberans in the Breast. <i>Breast Journal</i> , 2005, 11, 217-218. | 1.0 | 15 |
| 196 | Potential Targets to Encourage a Surgical Career. <i>Journal of the American College of Surgeons</i> , 2005, 200, 946-953. | 0.5 | 99 |
| 197 | Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. <i>Surgery</i> , 2005, 138, 422-430. | 1.9 | 23 |
| 198 | Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: The potential role of partial breast irradiation. <i>Women's Oncology Review</i> , 2005, 5, 75-76. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | COX-2 overexpression increases motility and invasion of breast cancer cells. International Journal of Oncology, 2005, 26, 1393. | 3.3 | 54 |
| 200 | Assessment of the Current Medicare Reimbursement System for Breast Cancer Operations. Breast Diseases, 2005, 16, 111-114. | 0.0 | 1 |
| 201 | Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. American Journal of Surgery, 2005, 190, 598-601. | 1.8 | 12 |
| 202 | Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: The potential role of partial breast irradiation. Women's Oncology Review, 2005, 5, 75-76. | 0.0 | 1 |
| 203 | Site of primary tumor has a prognostic role in operable breast cancer: The International Breast Cancer Group experience. Colleoni, D. Zahrieh, R.D. Gelber, S.B. Holmberg, J.E. Mattsson, C.-M. Rudenstam, J. Lindtner, D. Erzen, R. Snyder, J. Collins, et al. JCO 2005;23(7):1390-1400. Women's Oncology Review, 2005, 5, 173-174. | 0.0 | 0 |
| 204 | COX-2 overexpression increases motility and invasion of breast cancer cells. International Journal of Oncology, 2005, 26, 1393-9. | 3.3 | 72 |
| 205 | A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. Journal of the American College of Surgeons, 2004, 199, 644-651. | 0.5 | 34 |
| 206 | Assessment of the Current Medicare Reimbursement System for Breast Cancer Operations. Annals of Surgical Oncology, 2004, 11, 1037-1044. | 1.5 | 12 |
| 207 | Giant pelvic schwannoma with ancient change. Journal of the American College of Surgeons, 2003, 197, 163. | 0.5 | 5 |
| 208 | Factors influencing career choice among medical students interested in surgery. Journal of Surgical Education, 2003, 60, 210-213. | 0.7 | 152 |
| 209 | Mastectomy performed with scissors following tumescent solution injection. Journal of Surgical Oncology, 2003, 83, 191-193. | 1.7 | 19 |
| 210 | Neoadjuvant Trastuzumab and Docetaxel in Patients With Breast Cancer: Preliminary Results. Clinical Breast Cancer, 2003, 4, 348-353. | 2.4 | 92 |
| 211 | Brief intervention by surgeons can influence students toward a career in surgery. Journal of Surgical Research, 2003, 111, 166-169. | 1.6 | 128 |
| 212 | Relapse of Thrombotic Thrombocytopenic Purpura Associated with Decreased VWF Cleaving Activity. American Journal of the Medical Sciences, 2002, 323, 281-284. | 1.1 | 9 |
| 213 | Role of Cyclooxygenase-2 in Breast Cancer. Journal of Surgical Research, 2002, 108, 173-179. | 1.6 | 101 |
| 214 | Assessment of Knowledge of Melanoma Risk Factors, Prevention, and Detection Principles in Texas Teenagers. Journal of Surgical Research, 2001, 97, 179-183. | 1.6 | 31 |
| 215 | A caution regarding lymphatic mapping in patients with colon cancer. American Journal of Surgery, 2001, 182, 707-712. | 1.8 | 73 |
| 216 | National practice patterns of sentinel lymph node dissection for breast carcinoma. No competing interests declared. Journal of the American College of Surgeons, 2001, 192, 453-458. | 0.5 | 112 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 1682-1687. | 3.4 | 264 |
| 218 | Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 219 | Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. <i>Annals of Surgical Oncology</i> , 0, , . | 1.5 | 2 |